研究单位：[1]Akeso[2]AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China[3]AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical College,Wuhu,Anhui,China[4]AkesoBio Investigative Site 1001, Peking University People's Hospital,Beijing,Beijing,China[5]AkesoBio Investigative Site 2044, Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China[6]AkesoBio Investigative Site 2023, Xinqiao Hospital Medical University,Chongqing,Chongqing,China[7]AkesoBio Investigative Site 2024, Chongqing Three Gorges Medical College,Chongqing,Chongqing,China[8]AkesoBio Investigative Site 2040, Chongqing Traditional Chinese Medicine Hospital,Chongqing,Chongqing,China[9]AkesoBio Investigative Site 2052, The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China[10]AkesoBio Investigative Site 2038, The First Affiliated Hospital of Fujian Medical University,Fuzhou,Fujian,China[11]AkesoBio Investigative Site 2022, Dongguan People's Hospital,Dongguan,Guangdong,China[12]AkesoBio Investigative Site 1002, Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China[13]AkesoBio Investigative Site 2003, Dermatology Hospital of Southern Medical University,Guangzhou,Guangdong,China[14]AkesoBio Investigative Site 2049, The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China[15]AkesoBio Investigative Site 2004, The First Affiliated Hospital of Hainan Medical University,Haikou,Hainan,China[16]AkesoBio Investigative Site 2001, Affiliated Hospital of Chengde medical university,Chengde,Hebei,China[17]AkesoBio Investigative Site 2010, Nanyang First People's Hospital National Third Class A Hospital,Nanyang,Henan,China[18]AkesoBio Investigative Site 2051, Jingzhou Central Hospital,Jingzhou,Hubei,China[19]AkesoBio Investigative Site 1005, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China[20]AkesoBio Investigative Site 2046, The Third Xiangya Hospital of Central South University,Changsha,Hunan,China[21]AkesoBio Investigative Site 2008, The Affiliated Hospital of Inner Mongolia Medical University,Hohhot,Inner Mongolia,China[22]AkesoBio Investigative Site 2048, The First People's Hospital of Changzhou,Changzhou,Jiangsu,China[23]AkesoBio Investigative Site 2050, Wuxi Second People's Hospital,Wuxi,Jiangsu,China[24]AkesoBio Investigative Site 2025, Affiliated Hospital of Jiangsu University,Zhenjiang,Jiangsu,China[25]AkesoBio Investigative Site 2032, The First Affiliated Hospital of Gannan Medical College,Ganzhou,Jiangxi,China[26]AkesoBio Investigative Site 2011, Northeast International Hospital,Shenyang,Liaoning,China[27]AkesoBio Investigative Site 2039, Shandong Provincial Dermatology Hospital,Jinan,Shandong,China[28]AkesoBio Investigative Site 2041, Qilu Hospital of Shandong University,Jinan,Shandong,China[29]AkesoBio Investigative Site 1003, Shanghai Skin Disease Hospital,Shanghai,Shanghai,China[30]AkesoBio Investigative Site 2027, Medical School of Yanan University,Xianyang,Shanxi,China[31]AkesoBio Investigative Site 2029, West China Hospital，Sichuan University,Chengdu,Sichuan,China[32]AkesoBio Investigative Site 2034, Chengdu Second People's Hospital,Chengdu,Sichuan,China[33]AkesoBio Investigative Site 2013, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin,Tianjin,China[34]AkesoBio Investigative Site 2019, Tianjin Medical University General Hospital,Tianjin,Tianjin,China[35]AkesoBio Investigative Site 2043, First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China[36]AkesoBio Investigative Site 1004, Zhejiang Provincial People's Hospital,Hangzhou,Zhejiang,China[37]AkesoBio Investigative Site 2006,Affiliated Hangzhou First People's Hospital,Hangzhou,Zhejiang,China[38]AkesoBio Investigative Site 2007, Hangzhou Third People's Hospital,Hangzhou,Zhejiang,China[39]AkesoBio Investigative Site 2035, The Second Affiliated Hosp
研究目的：
This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
